dc.contributor.author |
Ahmed Kamal, Manar |
|
dc.contributor.author |
Al- Arawi, Raneem Mahmoud |
|
dc.contributor.author |
Kamal, Mohamed Ahmed |
|
dc.date.accessioned |
2022-12-23T09:16:28Z |
|
dc.date.available |
2022-12-23T09:16:28Z |
|
dc.date.issued |
2022-12 |
|
dc.identifier.other |
https://doi.org/10.1016/j.ahj.2022.10.015 |
|
dc.identifier.uri |
http://repository.msa.edu.eg/xmlui/handle/123456789/5289 |
|
dc.description.abstract |
Background: Type 2 diabetes mellitus (T2DM) trig-
gers long-lasting and progressive metabolic disorders,
causing a severe health issue resulting in several high pre-
dominance and dangerous complications. Liraglutide is
a glucagon-like peptide-1 (GLP-1), while gliclazide is an
oral antihyperglycemic agent.
Objectives: To measure the efficacy of gliclazide and
liraglutide on T2DM patients.
Methods: We performed systematic reviews and meta-
analyses by searching two databases, PubMed and Web of
Science (WOS), for relevant studies published in the lit-
erature during May 2021. We included clinical trials and
observational studies and extracted the patients’ base-
line characteristics and outcomes. We used the Cochrane
Handbook of Systematic Reviews of Interventions and
the Newcastle Ottawa scale to assess the included stud-
ies’ quality. The statistical analysis was performed by
STATA Version 16.
Results: Our meta-analysis included three studies (two
clinical trials and one observational study) with 137
participants, 71 in the gliclazide and 66 in the liraglu-
tide groups. Gliclazide had a non-significant reduction
of glycated hemoglobin (HbA1c) compared to liraglu-
tide (mean difference [MD] 0.53; 95% CI -0.01, 1.07;
P = 0.06). Gliclazide had a non-significant decreasing of
body weight compared to liraglutide (standardized mean
difference [SMD] 0.32; 95% CI -0.02, 1.07; P = 0.06). Gli-
clazide had a non-significant decreasing of low-density
lipoprotein cholesterol (LDL-C) and high-density lipopro-
tein cholesterol (HDL-C) compared to liraglutide (SMD -
0.11; 95% CI -0.45, 0.23; P = 0.53) and (MD -0.02; 95% CI
-0.15, 0.10; P = 0.7).
Conclusions: Liraglutide is more effective in reducing
HbA1c, body weight LDL-C, and HDL-C than gliclazide.
https://doi.org/10.1016/j.ahj.2022.10.016 |
en_US |
dc.language.iso |
en_US |
en_US |
dc.publisher |
Mosby Inc. |
en_US |
dc.relation.ispartofseries |
American Heart Journal;254:236 |
|
dc.title |
Efficacy of Liraglutide Versus Gliclazide in Treatment of Patients with Type II Diabetes Mellitus: Systematic Review and Meta-Analysis |
en_US |
dc.type |
Article |
en_US |